Pharma BD Deal Intelligence
Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility)
2011 · Asset Purchase · Complete
Announcement Sentiment
79
Strongly positive
Boehringer Ingelheim acquired Amgen's Fremont, California biologics manufacturing facility, expanding Boehringer's biopharma contract manufacturing capacity. Closed March 2011. Financial terms not disclosed.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
- Announced Jan 21, 2011
- Closed Mar 01, 2011
- Deal type Asset Purchase
- Therapeutic area Biologics CMO/manufacturing
- Indications Biologics CMO/manufacturing
- Key assets Biologics manufacturing facility
- Mechanism Mammalian cell-culture biologics manufacturing
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals